Pathologic diagnosis of recurrent glioblastoma: Morphologic, immunohistochemical, and molecular analysis of 20 paired cases

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 620-628

  Kim, Jang Hee ^a   Bae Kim, Young ^a   Han, Jae Ho ^a   Cho, Kyung Gi ^a,c   Kim, Se Hyuk ^a   Sheen, Seung Soo ^b   Lee, Hyun Woo ^a   Jeong, Seon Yong ^a   Kim, Bo Young ^a   Lee, Kyi Beom ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c CHA University   (South Korea)

Author keywords

glioblastoma; isocitrate dehydrogenase; Ki 67 antigen; pathology; recurrence

Indexed keywords

DNA; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN; BRAIN TUMOR; FEMALE; GENETICS; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; NECROSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR RECURRENCE;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; DNA, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859098891     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318246040c     Document Type: Article

References (26)

1. Burger PC, Scheithauer BW. Tumors of neuroglia and choroid plexus. In: Tomas DS, ed. Tumours of the Central Nervous System AFIP Atlas of Tumor Pathology. Washington, DC: American Registry of Pathology 2007:55-77.
2. Capper D, Sahm F, Hartmann C, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34:1199-1204.
3. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
4. Forsyth PA, Kelly PJ, Cascino TL, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg. 1995;82:436-444.
5. Gasparetto EL, Pawlak MA, Patel SH, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology. 2009;250:887-896.
6. Grunkemeier MN, Turner K, McLendon RE. Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR. Acta Neuropathol. 2007;113:217-219.
7. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
8. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol. 2009;30:552-558.
9. Jain R, Scarpace L, Ellika S, et al. First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery. 2007;61:778-786.
10. Keles GE, Lamborn KR, Chang SM, et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004;100:41-46.
11. Kim HS, Kim JH, Kim SH, et al. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. Radiology. 2010; 256:906-915.
12. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN OH, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer 2007:33-49.
13. Litofsky NS, Mix TC, Baker SP, et al. Ki-67 (clone MIB-1) proliferation index in recurrent glial neoplasms: no prognostic significance. Surg Neurol. 1998;50:579-585.
14. Martinez R, Rohde V, Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol. 2010;96:321-329.
15. McGirt MJ, Bulsara KR, Cummings TJ, et al. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg. 2003;98:14-20.
16. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 2006;76: 193-200.
17. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002-6007.
18. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
19. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol. 2006;111:197-212.
20. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery. 2004;54:1111-1117; discussion 1117-1119.
21. Schroder R, Feisel KD, Ernestus RI. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. J Neurooncol. 2002;56:127-132.
22. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256.
23. Srinivasan R, Phillips JJ, Vandenberg SR, et al. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 2010;12:1152-1161.
24. Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-123.
25. Tihan T, Barletta J, Parney I, et al. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol. 2006;37:272-282.
26. Wen PY, Norden AD, Drappatz J, et al. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010;12: 68-75.